eLife Sciences highlights five practical insights from the ISPE Nordic-Baltic Validation Summit in Vilnius on the future of GxP validation.
GxP is the umbrella term for the regulations governing manufacturing, testing, and distribution across pharma, biotech, and medtech. Understanding what GxP compliance actually requires is the starting point for any organization operating in a regulated environment.
Digital transformation in a GxP environment is not just another IT rollout — it’s a controlled shift in how quality, validation, and data are managed. Get it wrong, and you risk regulatory non-compliance. Here’s how eLife Sciences approaches it the right way.
Annex 22 is the first EU GMP standard designed specifically to govern artificial intelligence and machine learning within regulated pharmaceutical environments. Once finalized, it will apply directly to manufacturers of active substances and medicinal products operating under GxP.
EU Annex 11 is the cornerstone framework regulating the use of computerized systems in the European pharmaceutical industry. It sets strict expectations for software validation, data integrity, and system security. For any life sciences organization using digital tools in GxP environments, understanding and implementing these rules is non-negotiable.
CQV stands for Commissioning, Qualification and Validation — the structured process that confirms facilities, systems, and equipment in regulated environments are ready to operate exactly as designed, before they go live. For life sciences manufacturers, this isn’t a single hand-off inspection; it’s a documented, risk-based pathway that reduces failure risk and builds the evidence base regulators expect to see. Done well, CQV turns a chaotic start-up into a predictable, audit-ready launch.
